Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals

AIDS

Volumn 28, Issue 7, 2014, Pages 949-957

  Esbjörnsson, Joakim ^a,b,c,d   Månsson, Fredrik ^e   Kvist, Anders ^f   Isberg, Per Erik ^g   Biague, Antonio J ^h   Da Silva, Zacarias J ^h   Jansson, Marianne ^a,c   Fenyö, Eva Maria ^a   Norrgren, Hans ^f   Medstrand, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e LUND UNIVERSITY   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g LUND UNIVERSITY SCHOOL OF ECONOMICS AND MANAGEMENT   (Sweden)

^h National Public Health Laboratory   (Guinea-Bissau)

Author keywords

dual infection; HIV 1; HIV 2; mortality; survival

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MORTALITY; POLICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; SURVIVAL RATE; SURVIVAL TIME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; SURVIVAL; VIROLOGY;

ADULT; COHORT STUDIES; COINFECTION; FEMALE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84897491606     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000101     Document Type: Article

References (72)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
2. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343-346.
3. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Gueye NA, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943-946.
4. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-1590.
5. Simon F, Matheron S, Tamalet C, Loussert-Ajaka I, Bartczak S, Pepin JM, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411-1417.
6. Andersson S, Norrgren H, da Silva Z, Biague A, Bamba S, Kwok S, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160:3286-3293.
7. Hamel DJ, Sankale JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses 2007; 23:1189-1196.
8. Mansson F, Biague A, da Silva ZJ, Dias F, Nilsson LA, Andersson S, et al. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS 2009; 23:1575-1582.
9. Travers K, Mboup S, Marlink R, Gueye-Nidaye A, Siby T, Thior I, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612-1615.
10. Norrgren H, Andersson S, Biague AJ, da Silva ZJ, Dias F, Naucler A, et al. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. AIDS 1999; 13:701-707.
11. Aaby P, Poulsen AG, Larsen O, Christiansen CB, Jensen H, Melbye M, et al. Does HIV-2 protect against HIV-1 infection? AIDS 1997; 11:939-940.
12. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001; 15:2319-2321.
13. Schim van der Loeff MF, Aaby P, Aryioshi K, Vincent T, Awasana AA, Da Costa C, et al. HIV-2 does not protect against HIV-1 infection in a rural community in Guinea-Bissau. AIDS 2001; 15:2303-2310.
14. Wiktor SZ, Nkengasong JN, Ekpini ER, Adjorlolo-Johnson GT, Ghys PD, Brattegaard K, et al. Lack of protection against HIV-1 infection among women with HIV-2 infection. AIDS 1999; 13:695-699.
15. de Silva T, van Tienen C, Rowland-Jones S, Cotten M. Dual infection with HIV-1 and HIV-2: double trouble or destructive interference? HIV Ther 2010; 4:305-323.
16. Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012; 367: 224-232.
17. Prince PD, Matser A, Van Tienen C, Whittle HC, Schim Van Der Loeff MF. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS 2013[Epub ahead of print].
18. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17:343-346.
19. Andersson S, da Silva Z, Norrgren H, Dias F, Biberfeld G. Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2-prevalent area. AIDS 1997; 11:1815-1822.
20. Walther-Jallow L, Andersson S, da Silva Z, Biberfeld G. High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses 1999; 15:957-962.
21. Greenberg AE, Wiktor SZ, Decock KM, Smith P, Jaffe HW, Dondero TJ Jr. HIV-2 and natural protection against HIV-1 infection. Science 1996; 272:1959a.
22. Otten RA, Adams DR, Kim CN, Pullium JK, Sawyer T, Jackson E, et al. Chronic HIV-2 infection protects against total CD4R cell depletion and rapid disease progression induced by SHIV89.6p challenge. AIDS 2004; 18:1127-1135.
23. Putkonen P, Thorstensson R, Albert J, Hild K, Norrby E, Biberfeld P, et al. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990; 4:783-789.
24. Arya SK, Gallo RC. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection. Proc Natl Acad Sci USA 1996; 93:4486-4491.
25. Kokkotou EG, Sankale JL, Mani I, Gueye-Ndiaye A, Schwartz D, Essex ME, et al. In vitro correlates of HIV-2-mediated HIV-1 protection. Proc Natl Acad Sci USA 2000; 97:6797-6802.
26. Akimoto H, Kaneko H, Sekigawa I, Hashimoto H, Kaneko Y, Yamamoto N. Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production. Immunology 1998; 95:214-218.
27. Al-Harthi L, Owais M, Arya SK. Molecular inhibition of HIV type 1 by HIV type 2: effectiveness in peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1998; 14:59-64.
28. Zheng NN, Kiviat NB, Sow PS, Hawes SE, Wilson A, Diallo-Agne H, et al. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1-and HIV-2-infected individuals in Senegal. J Virol 2004; 78:13934-13942.
29. Zheng NN, McElrath MJ, Sow PS, Hawes SE, Diallo-Agne H, Stern JE, et al. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J Virol 2007; 81:9061-9071.
30. Weiss RA, Clapham PR, Weber JN, Whitby D, Tedder RS, O'Connor T, et al. HIV-2 antisera cross-neutralize HIV-1. AIDS 1988; 2:95-100.
31. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends Microbiol 2008; 16:588-595.
32. Esbjörnsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague A, et al. Effect of HIV-2 infection on HIV-1 disease progression and mortality. AIDS 2014; 28:614-615.
33. van Tienen C, Schim van der Loeff M, Peterson I, Cotten M, Andersson S, Holmgren B, et al. HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community. PLoS One 2011; 6:e29026.
34. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008; 22:1195-1202.
35. Mansson F, Alves A, Silva ZJ, Dias F, Andersson S, Biberfeld G, et al. Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998 1999. Sex Transm Infect 2007; 83:463-467.
36. van der Loeff MF, Awasana AA, Sarge-Njie R, van der Sande M, Jaye A, Sabally S, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006; 35:1322-1328.
37. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
38. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343-346.
39. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Gueye NA, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943-946.
40. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-1590.
41. Simon F, Matheron S, Tamalet C, Loussert-Ajaka I, Bartczak S, Pepin JM, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411-1417.
42. Andersson S, Norrgren H, da Silva Z, Biague A, Bamba S, Kwok S, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160:3286-3293.
43. Hamel DJ, Sankale JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses 2007; 23:1189-1196.
44. Mansson F, Biague A, da Silva ZJ, Dias F, Nilsson LA, Andersson S, et al. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS 2009; 23:1575-1582.
45. Travers K, Mboup S, Marlink R, Gueye-Nidaye A, Siby T, Thior I, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612-1615.
46. Norrgren H, Andersson S, Biague AJ, da Silva ZJ, Dias F, Naucler A, et al. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. AIDS 1999; 13:701-707.
47. Aaby P, Poulsen AG, Larsen O, Christiansen CB, Jensen H, Melbye M, et al. Does HIV-2 protect against HIV-1 infection? AIDS 1997; 11:939-940.
48. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001; 15:2319-2321.
49. Schim van der Loeff MF, Aaby P, Aryioshi K, Vincent T, Awasana AA, Da Costa C, et al. HIV-2 does not protect against HIV-1 infection in a rural community in Guinea-Bissau. AIDS 2001; 15:2303-2310.
50. Wiktor SZ, Nkengasong JN, Ekpini ER, Adjorlolo-Johnson GT, Ghys PD, Brattegaard K, et al. Lack of protection against HIV-1 infection among women with HIV-2 infection. AIDS 1999; 13:695-699.
51. de Silva T, van Tienen C, Rowland-Jones S, Cotten M. Dual infection with HIV-1 and HIV-2: double trouble or destructive interference? HIV Ther 2010; 4:305-323.
52. Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012; 367: 224-232.
53. Prince PD, Matser A, Van Tienen C, Whittle HC, Schim Van Der Loeff MF. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS 2013[Epub ahead of print].
54. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17:343-346.
55. Andersson S, da Silva Z, Norrgren H, Dias F, Biberfeld G. Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2-prevalent area. AIDS 1997; 11:1815-1822.
56. Walther-Jallow L, Andersson S, da Silva Z, Biberfeld G. High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses 1999; 15:957-962.
57. Greenberg AE, Wiktor SZ, Decock KM, Smith P, Jaffe HW, Dondero TJ Jr. HIV-2 and natural protection against HIV-1 infection. Science 1996; 272:1959a.
58. Otten RA, Adams DR, Kim CN, Pullium JK, Sawyer T, Jackson E, et al. Chronic HIV-2 infection protects against total CD4R cell depletion and rapid disease progression induced by SHIV89.6p challenge. AIDS 2004; 18:1127-1135.
59. Putkonen P, Thorstensson R, Albert J, Hild K, Norrby E, Biberfeld P, et al. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990; 4:783-789.
60. Arya SK, Gallo RC. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection. Proc Natl Acad Sci USA 1996; 93:4486-4491.
61. Kokkotou EG, Sankale JL, Mani I, Gueye-Ndiaye A, Schwartz D, Essex ME, et al. In vitro correlates of HIV-2-mediated HIV-1 protection. Proc Natl Acad Sci USA 2000; 97:6797-6802.
62. Akimoto H, Kaneko H, Sekigawa I, Hashimoto H, Kaneko Y, Yamamoto N. Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production. Immunology 1998; 95:214-218.
63. Al-Harthi L, Owais M, Arya SK. Molecular inhibition of HIV type 1 by HIV type 2: effectiveness in peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1998; 14:59-64.
64. Zheng NN, Kiviat NB, Sow PS, Hawes SE, Wilson A, Diallo-Agne H, et al. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1-and HIV-2-infected individuals in Senegal. J Virol 2004; 78:13934-13942.
65. Zheng NN, McElrath MJ, Sow PS, Hawes SE, Diallo-Agne H, Stern JE, et al. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J Virol 2007; 81:9061-9071.
66. Weiss RA, Clapham PR, Weber JN, Whitby D, Tedder RS, O'Connor T, et al. HIV-2 antisera cross-neutralize HIV-1. AIDS 1988; 2:95-100.
67. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends Microbiol 2008; 16:588-595.
68. Esbjörnsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague A, et al. Effect of HIV-2 infection on HIV-1 disease progression and mortality. AIDS 2014; 28:614-615.
69. van Tienen C, Schim van der Loeff M, Peterson I, Cotten M, Andersson S, Holmgren B, et al. HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community. PLoS One 2011; 6:e29026.
70. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008; 22:1195-1202.
71. Mansson F, Alves A, Silva ZJ, Dias F, Andersson S, Biberfeld G, et al. Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998 1999. Sex Transm Infect 2007; 83:463-467.
72. van der Loeff MF, Awasana AA, Sarge-Njie R, van der Sande M, Jaye A, Sabally S, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006; 35:1322-1328.